Arcutis Biotherapeutics Inc. (ARQT) — RQD Stock Rating Cockpit
Arcutis Biotherapeutics Inc. (ARQT) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Weak cash conversion or heavy valuation strain compared to actual cash earned.
Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.
Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.
JEV AI Jury Split (Battleground) on ARQT
-3.0% ROIC with 90.2% gross margin and -0.16% FCF yield.
Altman-Z 7.78 and Piotroski 6/9 pass balance-sheet audit.
Put/Call 0.64x with 22/40 institutional & insider flow.
- ✓Clean SEC annual filing review with no major hidden accounting time-bombs.
- !Broader market pullbacks can still drag down strong stocks in the short run.
Today's Top 3 RQD Strong Buys & Whale Accumulation Setups (Live ARQT Tape Review)
- ✓Live breakdown of today’s highest-scoring RQD Green-Light breakouts
- ✓1 urgent Red-Light accounting trap to cut from your watchlist immediately
- ✓Bring any ticker to live Q&A—we run it through the 5-Pillar RQD Radar on screen
ARQT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +91.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ARQT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ARQT. Explore sector supply chains on /butterfly.
ARQT Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDShould I buy, hold, or sell ARQT stock right now?
Arcutis Biotherapeutics Inc. (ARQT) currently earns a Roarable Rating of C (Hold — HOLD) with 63/100 RQD Confidence. Solid 90% profit margin (-3% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
What is ARQT's 12-month price target and RQD AI Jury consensus?
ARQT's 12-month base price target is $32.69 (range $25.5 to $38.57), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.